Wyeth (WYE) Updates Ongoing Litigation
More News related to WYE
- Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
- Wyeth (WYE) Extends Collaboration Agreement With Trubion Pharmaceuticals (TRBN)
- Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
- Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
- New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market
In Today's 8-K Filing From Wyeth (NYSE: WYE): With regard to our diet drug litigation involving the products REDUX and PONDIMIN described in our 2006 Financial Report, the case of Madsen v. American Home Products Corporation, et al., No. 4:02CV01835 ERW, U.S.D.C., E.D. Mo., was dismissed following the granting of our motion for summary judgment.
In the product liability litigation involving our hormone therapy products described in our 2006 Financial Report, the New York Supreme Court, Onondaga County, had granted summary judgment in favor of us, dismissing the claims in Browning, et al. v. Wyeth, Inc., et al., No. 2003-0261, on the grounds, inter alia, that the labeling and warnings for PREMPRO and PREMARIN were adequate as a matter of law.
As discussed in our 2006 Financial Report, we have filed suit against multiple generic companies that have filed Abbreviated New Drug Applications (ANDA) seeking the U.S. Food and Drug Administration (FDA) approval to market generic 37.5 mg, 75 mg and 150 mg venlafaxine HCl extended release capsules. Venlafaxine HCl is the active ingredient used in EFFEXOR XR. On March 12, 2007, we filed suit in the United States District Court for the District of Maryland against Lupin Ltd. and Lupin Pharmaceuticals, Inc., alleging that the filing by Lupin of an ANDA seeking FDA approval to market 37.5 mg, 75 mg and 150 mg venlafaxine HCl extended release capsules infringes our patents relating to methods of using extended release formulations of venlafaxine HCl.
Related Categories
Corporate NewsStocks Mentioned
-15.56Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
